一、基本信息
姓名：王青
职称：教授，主任医师，研究员
联系邮箱：wqdennis@126.com
二、学业和工作经历
学业经历
1990.9-1995.7 湖南医科大学，临床医学专业，学士；
1997.6-2000.7 中山医科大学，神经病学专业，硕士；
2001.7-2005.3 新加坡国立大学医学院，神经药理专业，博士
工作经历
1995.7-2001.7 中山医科大学第三附属医院，康复及神经内科, 医生（2000年 12月至2001年6月神经内科住院总）
2005.3-2005.10 新加坡国立大学附属医院神经内科，新加坡神经内科注册医生
2005.10-2006.10 美国斯坦福大学医学院神经研究所，博士后研究员；
2006.11-2009. 2 澳洲卧龙岗大学医学院神经生物研究中心，澳洲国家健康及医学科学研究院研究员；
2009.2-2017. 7 中山大学附属第三医院神经内科，神经科副主任 博士生导师；
2017.8-至今 南方医科大学珠江医院神经内科，神经科主任 教授（三级岗）主任医师 博士生导师
三、拟招收博士后开展的研究方向
1. 神经退行性疾病PD/MSA/PSP/Dementia的发病机制；
2. 神经退行性疾病Dementia的再生机制研究；
3. 脑血管病如脑小血管疾病的发病机制研究；
4. 痴呆的发病机制。
四、主要学术任职
1. 美国神经科学会（Society for Neuroscience），委员；
2. 亚太神经化学学（Asia Pacific Society for Neurochemistry），委员；
3. 中国老年保健医学研究会，老年认知心理疾病分会中青年委员会，副主任委员；
4. 中华医学会神经病学分会帕金森及运动障碍学组，全国学组委员；
5. 中国医师学会神经病学分会帕金森及运动障碍专业委员会，全国学组委员；
6. 广东省医学会神经病学分会帕金森及运动障碍学组，委员；
7. 广东省神经药理学会，常务委员；
8. Frontiers in Cellular Neuroscience (IF: 4.5; ISSN 16625102)，Editor Member；
9. Aging and Disease (IF: 5.1)，Editor Member；
10. International Journal of Neurology Research (ISSN 2313-5611)，Editor Member；
11. Neuroimmunology and Neuroinflammation (ISSN2349-6142)，Editor Member；
12. Central Nervous System Agents in Medicinal Chemistry (ISSN 1875-6166), Regional Editor；
13. PLoS One(ISSN 1932-6203), 杂志特邀审稿评委；
14. Stroke (ISSN 0039-2499 )，杂志特邀审稿评委；
15. Neuroscience（ISSN 0306-4522），杂志特邀审稿评委；
16. Neurobiology of Disease（ISSN 0969-9961），杂志特邀审稿评委；
17. Neuroscience Letters（ISSN 0304-3940），杂志特邀审稿评委；
18. Neural Regeneration Research（ISSN 1673-5374），杂志特邀审稿评委。
五、主要获奖情况
1. 广东省杰出青年医学人才，2018；
2. 广东特支百千万领军人才，2016；
3. 十大中国杰出神经内科医师（青年医师奖），2016；
4. Brain 2013 and Brain PET2013, 旅行奖， 2013；
5. 教育部新世纪人才，2010；
6. 中山大学“-”引进人才，2009；
7. 第8届亚太地区神经化学年会第三次特别会议，旅行奖，2008；
8. 美国心脏协会青年科学家论坛，荣誉提名奖，2006；
9. 第6届亚太地区神经化学年会，旅行奖，2004；
10. 第7届新加坡科学年会，青年科学家奖，2003；
11. 论文“高糖对缺氧神经元的损害及西比灵的保护作用” 全国神经科学会征文一等奖，2000。
六、代表性论文
1. Qin Yang, Zifeng Huang, Yangfu Luo, Fangshuo Zheng, Yida Hu, Hui Liu, Shuzhen Zhu, Miaoqing He, Demei Xu, Yun Li, Min Yang, Yi Yang, Xiaobo Wei, Xiaoya Gao, Wei Wang, Junhong Ma, Yuanlin Ma, Xuefeng Wang*, Qing Wang*. Inhibition of Nwd1 activity attenuates neuronal hyperexcitability and GluN2B phosphorylation in the hippocampus. EBioMedicine 2019, 47:470-483 (Impact factor: 6.68)
2. Shuzhen Zhu, Xiaobo Wei1, Xiaohua Yang1, Zifeng Huang, Zihan Chang, Fen Xie, Qin Yang, Wei Xiang, Hongjun Yang, Changhai Ding, Ying Xia, Zhong-Ping Feng, Hong-Shuo Sun, Midori A. Yenari, Lin Shi, Vincent CT Mok, Qing Wang*. Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment. Aging and Disease. 2019；10(4):834-846 (IF: 5.1).
3. Yang Q, Zheng F, Hu Y, Yang Y, Li Y, Chen G, Wang W, He M, Zhou R, Ma Y, Xu D, Tian X, Gao X, Wang Q*, Wang X*. ZDHHC8 critically regulates seizure susceptibility in epilepsy. Cell Death Dis. 2018; 9(8):795. (Impact factor: 5.65).
4. Tao X, Yang W, Zhu S, Que R, Liu C, Fan T, Wang J, Mo D, Zhang Z, Tan J, Jin K, Yenari MA, Song T, Wang Q*. Models of poststroke depression and assessments of core depressive symptoms in rodents: How to choose? Exp Neurol. 2019; 322:113060. (Impact factor: 4.6).
5. Xie F, Gao X, Yang W, Chang Z, Yang X, Wei X, Huang Z, Xie H, Yue Z, Zhou F, Wang Q*. Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson's Disease. ACS Chem Neurosci. 2019;10(2):973-990 (IF: 4.4).
6. Xiaoya Gao, Haiting Xie, Shuzhen Zhu, Bin Yu, Ying Xian, Qian Ouyang, Yabin Ji, Xiaohua Yang, Chunyan Wen, Penghua Wang, Yufeng Tong, Qing Wang*. The Combination of Human Urinary Kallidinogenase and Mild Hypothermia Protects Adult Rats against Hypoxic-ischemic Encephalopathy-induced Injury by Promoting Angiogenesis and Regeneration. Front Aging Neurosci. 2018;10:196. (Impact factor: 4.55).
7. Jing Zou, Zhigang Chen, Caiqian Liang, Yongmei Fu, Xiaobo Wei, Jianjun Lu, Mengqiu Pan, Yue Guo, Xinxue Liao,Huifang Xie, Duobin Wu MD, Ph.D 4, Min Li, Lihui Liang, Penghua Wang, Qing Wang *. Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson’s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage. Aging and Disease. 2018; 9(1):51-65 (Impact factor: 5.05).
8. Weng R, Wei X, Yu B, Zhu S, Yang X, Xie F, Zhang M, Jiang Y, Feng ZP, Sun HS, Xia Y, Jin K, Chan P, Wang Q*, Gao X*. Combined measurement of plasma cystatin C and low-density lipoprotein cholesterol: A valuable tool for evaluating progressive supranuclear palsy. Parkinsonism Relat Disord. 2018; 52:37-42 (Impact factor: 4.72).
9. Jing Zou, Zhaoyu Chen, Xiaobo Wei, Zhigang Chen, Yongmei Fu, Xiaoyan Yang, Dan Chen, Rui Wang , Peter Jenner, Jia-Hong Lu, Min Li, Zhuohua Zhang, Beisha Tang , Knlin Jin , Qing Wang *. Cystatin C as a Potential Therapeutic Mediator against Parkinson's Disease via VEGF-induced Angiogenesis and Enhanced Neuronal Autophagy in Neurovascular Units. Cell Death Dis. 2017; 8(6): e2854 (Impact factor: 5.985).
10. Rui Wang, Zhaoyu Chen, Yongmei Fu, Xiaobo Wei, Jinchi Liao, Xu Liu, Bingjun He, Yunqi Xu, Jing Zou, Xiaoyan Yang, Ruihui Weng, Sheng Tan, Christopher McElro, Kunlin Jin, Qing Wang* (2017) Plasma Cystatin C and High-density Lipoprotein are Important Biomarkers of Alzheimer’s Disease and Vascular Dementia: A Cross-Sectional Study. Front Aging Neurosci. 9:26 (Impact factor: 4.55).
11. Xiaobo Wei, Huimin Gao, Jing Zou, Xu Liu, Dan Chen, Jinchi Liao, Yunqi Xu, Long Ma, Beisha Tang, Zhuohua Zhang, Xiang Cai, Kunling Jin, Ying Xia, Qing Wang* (2016) Contra-directional coupling of Nur77 and Nurr1 in Neurodegeneration: A novel mechanism for Memantine-induced anti-inflammation and anti-mitochondrial impairment. Molecular Neurobiology. 53(9):5876-5892. (Impact factor: 6.2).
12. Xiaobo Wei, Ronghua Yan, Zhaoyu Chen, Ruihui Weng, Xu Liu, Huimin Gao, Xiaofeng Xu, Zhuang Kang, Zhexing Liu, Yan Guo, Zhenhua Liu, Sheng Tan, Jan Petter Larsen, Jin Wang, Beisha Tang, Mark Hallett, Qing Wang*. (2016) Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early PD. Scientific Reports: 6:33762 (Impact factor: 5.4).
13. Huimin Gao, Zhaoyu Chen, Yongmei Fu, Xiaoyan Yang, Ruihui Weng, Rui Wang, Jianjun Lu, Mengqiu Pan, Kunlin Jin, Chris McElroy, Beisha Tang, Ying Xia, Qing Wang* (2016). Nur77 exacerbates PC12 cellular injury in vitro by aggravating mitochondrial impairment and endoplasmic reticulum stress. Scientific Reports: 6:34403 (Impact factor: 5.4).
14. Mackovski N, Liao J, Weng R, Wei X, Wang R, Chen Z, Liu X, Yu Y, Meyer BJ, Xia Y, Deng C, Huang XF, Wang Q*. Reversal effect of simvastatin on the decrease in cannabinoid receptor 1 density in 6-hydroxydopamine lesioned rat brains. Life Sci. 2016; 155:123-32. (Impact factor: 2.7).
15. Chen D, Wei X, Zou J, Wang R, Liu X, Xu X, Lu J, Wang Z, Tang B, Wang B, Jin K, Wang Q*. (2015) Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study. Front Cell Neurosci ; 9: 247 (Impact factor: 4.6).
16. Jing Zou, Rui-Hui Weng, Zhao-Yu Chen, Xiao-Bo Wei, Rui Wang, Dan Chen, Ying Xia & Qing Wang. (2016) Position Emission Tomography/Single Photon Emission Tomography Neuroimaging for Detection of Pre-Motor Parkinson’s Disease. CNS Neuroscience & Therapeutics. 22(3):167-77 (Impact factor: 4.0).
17. Huimin Gao, Xiaobo Wei,Jinchi Liao, Rui Wang, Jiehua Xu, Xu Liu, Xiaoping
Pan, Ze Li, Zhong Li, Ying Xia, Qing Wang *. (2015) Lower bone mineral density in Patients with Parkinson’s disease: a cross-sectional study from Chinese Mainland. Front Aging Neurosci; 7:203 (Impact factor: 4.3).
18. Peng Zhou, Ruihui Weng, Zhaoyu Chen, Rui Wang, Jing Zou, Xu Liu, Jinchi Liao, Yanping Wang, Ying Xia, and Qing Wang (2016). TLR4 signaling in MPP+-induced activation of BV-2 cells. Neural Plasticity. 2016:5076740. (Impact factor: 3.6).
19. Yunqi Xu, Xiaobo Wei, Xu Liu, Jinchi Liao, Jiaping Lin, Peng Zhou, Cansheng Zhu, Xiaochun Meng, Dongsi Xie, Dongman Chao, Albert J Fenoy, Muhua Cheng, Beisha Tang, Ying Xia and Qing Wang* (2015). Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson’s disease. Aging and Disease. 6(6):426-436 (Impact factor: 5.05)
20. Long L, Cai XD, Wei XB, Xu YQ, Chen XH, Wang Q* (2015). Progressive supranuclear palsy: what do we know about it? Current Medicinal Chemistry. 22(10):1182-93 (Impact factor: 3.853).
21. Wang Q*, Wei X, Gao H, Li J, Liao J, Liu X, Qin B, Yu Y, Deng C, Tang B, Huang XF (2014). Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory. Neuroscience. 267, 57-66. (Impact factor: 3.327).
22. Wang Q*, Li J, Wei X, Liao J, Xu Y, Lu T, Qin B, Xie J, Deng C, Huang X (2014). Alterations of NMDA receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Int J Neurosci. 124, 457-465. (Impact factor:1.528).
23. Xu YQ, Long L, Yan JQ, Wei L, Pan MQ, Gao HM, Zhou P, Liu M, Zhu CS, Tang BS, Wang Q*（2013）.Simvastatin induces neuroprotection in 6-OHDA lesioned PC12 via the PI3K/AKT/Caspase 3 pathway and anti-inflammatory responses. CNS Neuroscience & Therapeutics. 19(3):170-7. (Impact factor: 4.0).
24. Pan M, Gao H, Long L, Xu Y, Liu M, Zou J, Wu A, Wei X, Chen X, Tang B, Wang Q* (2013). Serum uric acid in patients with Parkinson's disease and vascular parkinsonism: a cross-sectional study. Neuroimmunomodulation 20, 19-28. (Impact factor: 1.88).
25. Jiang Y, Zou Y, Chen S, Zhu C, Wu A, Liu Y, Ma L, Zhu D, Ma X, Liu M, Kang Z, Pi R, Peng F, Wang Q, Chen X (2013). The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice. Neuropharmacology.73C:415-424. (Impact factor: 5.01).
26. Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y, Wang Q* (2012). Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 97, 1-13. (Impact factor: 14.301).
27. Zhu C, Xiong Z, Chen X, Peng F, Hu X, Chen Y, Wang Q* (2012). Artemisinin Attenuates Lipopolysaccharide-Stimulated Proinflammatory Responses by Inhibiting NF-κB Pathway in Microglia Cells. PLoS One. 7(4): e35125 (Impact factor: 3.534).
28. Chen X, Ma L, Jiang Y, Chen S, Zhu C, Liu M, Ma X, Zhu D, Liu Y, Peng F, Wang Q*, Pi R (2012). Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Pharmacol. 686(1-3):124-9 (Impact factor: 2.684).
29. Wang Q*, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA (2011). Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 230, 27-34 (Impact factor: 4.617).
30. Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W, Wang Q*（2011）Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One. 6(6): e20945. (Impact factor: 3.534).
31. Zhang L, Yan J, Xu Y, Long L, Zhu C, Chen X, Jiang Y, Yang L, Bian L , Wang Q* (2011). The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism. PLoS One. 6, e19333 (Impact factor: 3.534).
32. Li H, Zhang M, Chen L, Zhang J, Pei Z, Hu A, Wang Q*(2010). Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease. Mov Disord. 25, 2740-2746 (Impact factor: 8.36).
33. Hu CH, Deng C, Mackovski N, Long L, Zhu C, Yang Y, Wang Y, Chen J, Huang XF, Wang Q*(2010). Effects of simvastatin and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains. Prog Neuropsychopharmacol Biol Psychiatry. 34(8):1419-25 (Impact factor: 4.025).
34. Li Y, Huang XF, Deng C, Meyer B, Wu A, Yu Y, Ying W, Yang GY, Yenari MA, Wang Q*(2010). Alterations in 5-HT2A receptor binding in various brain regions among 6-hydroxydopamine-induced Parkinsonian rats. Synapse. 64, 224-230 (Impact factor: 2.428).
35. Li ZR, Jiang ZB, Huang MS, Zhu KS, Wang Q, Shan H (2010). Transvenous embolization of cavernous sinus dural arteriovenous fistulas using detachable coils and Glubran 2 acrylic glue via the inferior petrosal sinus approach. Eur Radiol. 20, 2939-2947. (Impact factor: 4.338).
36. Wang Q*, Zengin A, Deng C, Li Y, Newell KA, Yang GY, Lu Y, Wilder-Smith EP, Zhao H, Huang XF (2009). High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol. 216, 132-138. (Impact factor: 4.617).
37. Kang K, Huang XF, Wang Q, Deng C (2009). Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study. Prog Neuropsychopharmacol Biol Psychiatry. 33(5):867-71. (Impact factor: 4.025).
38. Yu Y, Wang Q, Huang XF (2009). Energy-restricted pair-feeding normalizes low levels of brain-derived neurotrophic factor/tyrosine kinase B mRNA expression in the hippocampus, but not ventromedial hypothalamic nucleus, in diet-induced obese mice. Neuroscience. 160, 295-306. (Impact factor: 3.327).
39. Xia W, Wang Z, Wang Q, Han J, Zhao C, Hong Y, Zeng L, Tang L, Ying W (2009). Roles of NAD(+) / NADH and NADP(+) / NADPH in cell death. Curr Pharm Des. 15, 12-19. (Impact factor: 3.288).
40. Wang Q, van Hoecke M, Tang X, N Lee H, Zheng Z, Swanson R, A.Yenari M A.(2009). Pyruvate protects against experimental stroke via an anti-inflammatory mechanism. Neurobiology of Diseases. 36(1):223-31. (Impact factor: 5.202).
41. Wang Q*, Zengin A, Ying W, Newell KA, Wang P, Yeo W, Wong PT, Yenari MA, Huang XF (2008). Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. Neuroscience. 154, 1100-1106. （Cover Page）(Impact factor: 3.327).
42. Wang Q*, Huang XF (2008). Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Exp Neurol. 209, 261-267. (Impact factor:4.617).
43. Yu Y, South T, Wang Q, Huang XF (2008). Differential expression of hypothalamic CART mRNA in response to body weight change following different dietary interventions. Neurochem Int. 52, 1422-1430. (Impact factor: 2.65).
44. Huang XF, Yu Y, Li Y, Tim S, Deng C, Wang Q (2008). Ventromedial hypothalamic NPY Y2 receptor in the maintenance of body weight in diet-induced obesity in mice. Neurochem Res. 33, 1881-1888. (Impact factor: 2.551).
45. Wang Q, Tang XN, Yenari MA (2007). The inflammatory response in stroke. J Neuroimmunol. 184, 53-68. (Impact factor: 2.786).
46. Wang Q*, Aravinda KT, Lim EC, Chan YH, Deng C, Huang XF , Wilder-Smith EP (2007). A static handgrip method for distal quantitative sweat measurements. Neurosci Lett. 421, 229-233. (Impact factor: 2.055).
47. Huang XF, Tan YY, Huang X, Wang Q*(2007). Effect of chronic treatment with clozapine and haloperidol on 5-HT (2A and 2C) receptor mRNA expression in the rat brain. Neurosci Res. 59, 314-321. (Impact factor: 2.145).
48. Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA (2007). Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med. 48, 1822-1828. (Impact factor: 5.563).
49. Wei G, Wang D, Lu H, Parmentier S, Wang Q, Panter SS, Frey WN, Ying W (2007). Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front Biosci. 12, 4986-4996. (Impact factor: 4.249).
50. Ying W, Wei G, Wang D, Wang Q, Tang X, Shi J, Zhang P, Lu H (2007). Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front Biosci. 12, 2728-2734. (Impact factor: 4.249).
51. Tang XN, Wang Q, Xu LJ, Midori A. Yenari (2007). Blood-brain barrier disruption is related to NADPH oxidase in experimental stroke. Stroke 38 (2): 555-555. (Impact factor: 6.018).
52. Wang Q*, Tang XN, Wang L, Yenari MA, Ying W, Goh BC, Lee HS, Wilder-Smith EP, Wong PT (2006). Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett. 408(3):189-93. (Impact factor: 2.055).
53. Wang Q, Wee Lee Ting, Hongyuan Yang and Peter T-H Wong (2005). High doses of simvastatin up-regulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. British Journal of Pharmacology 144(7): 933-9. (Impact factor: 5.0).
54. Wang Q, Wang PH, McLachlan C, Wong PT (2005). Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 1045 (1-2), 229-233. (Impact factor: 2.828).
55. Wang Q, Zhu YZ, Steven MC, Ting WL, Yang HY, Wong PTH (2005). The HMG-COA reductase inhibitor, simvastatin up-regulates the dopamine D1 and D2 receptors expression in the frontal cortex among 6-hydroxy dopamine- lesioned rat. Journal of the Neurological Sciences. 87, 229-30. (Impact factor: 2.262).
56. Wang Q, Wong PT (2004). Concurrent up-regulation of eNOS and dopamine D1 and D2 receptor expression in the rat frontal cortex after simvastatin treatment. Journal of Neurochemistry. 88: 77-77 Suppl. (Impact factor: 4.244).
57. Farook JM, Wang Q, Moochhala SM, Zhu ZY, Lee L, Wong PT (2004) Distinct regions of periaqueductal gray (PAG) are involved in freezing behavior hooded PVG rats on the cat-freezing test apparatus. Neuroscience letters. 354(2), 139-142. (Impact factor: 2.055).
58. Farook JM, Zhu YZ, Wang Q, Moochhala SM, Lee L, Wong PT (2004) Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus. Neuroscience letters. 358 (3), 215-219. (Impact factor: 2.055).
* Corresponding Author (Selected JCR Year: 2013).
SELECTED PUBLISHED ABSTRACTS:
1. Qing Wang, Xiannan Tang, Aaron HM, Lee KH, Swanson RA, Midori A. Yenari (2007).Pyruvate protects against experimental stroke by inhibiting NF-kB activation. Stroke 38 (2): 551-551 (impact factors: 6.018)
2. Xiannan Tang, Qing Wang, Xu LJ, Midori A. Yenari (2007). Blood-brain barrier disruption is related to NADPH oxidase in experimental stroke. Stroke 38 (2): 555-555 (impact factors: 6.018).
3. Qing Wang, Wong PT (2004). Concurrent up-regulation of eNOS and dopamine D1 and D2 receptor expression in the rat frontal cortex after simvastatin treatment. Journal of Neurochemistry 88: 77-77 Suppl (impact factors: 4.244).
4. Qing Wang, Zhu YZ, Steven MC, Ting WL, Yang HY, Wong PTH (2005). The HMG-COA reductase inhibitor, simvastatin up-regulates the dopamine D1 and D2 receptors expression in the frontal cortex among 6-hydroxydopamine-lesioned rat. Journal of the Neurological Sciences 87, 229-30 (impact factors: 2.262)
INIVITED BOOK CHAPTER
1. Editor: Dr. Qing Wang, Weihai Ying (UCSF) Book：New Frontier in Neurological Research. ISBN: 978-81-308-0284-8. Publisher: Research Signpost, 2009.
2. Qing Wang (Corresponding Author), Kelly A Newell, Peter T-H Wong, Ying Lu. Chapter: Prefrontal cortex: its roles in cognitive impairment in Parkinson’s disease revealed by PET. Book：Prefrontal Cortex: Roles, Interventions and Traumas (2009). Editor: Prof. Frank Columbus; Publisher: Nova Science Publishers.
3. Xiannan Tang, Qing Wang, Midori A. Yenari. Chapter: Immunological mechanisms in ischemic stroke. Book：Role of the immune system on neurodegenerative diseases (2008). Editor: Prof. Antonio Ibarra; Publisher: Research Signpost. ISBN: 978-81-308-0261-9.
MAJOR SYMPOSIA ATTENDED AND TRACK RECORD
1. Qing Wang. Travel award obtained in the Brain 2013 and Brain PET2013 on May 20-23, 2013 in Shanghai, China.
2. Qing Wang. Attended US-China PD Research Collaboration Workshop sponsored by NSFC as one of the seven representatives in the nation on December 11th, 2011 in Washington DC, USA.
3. Qing Wang. Platform presentation at the XIX World Congress on Parkinson's Disease on December in Shanghai, China.
4. Qing Wang. Platform presentation at the 14th nation annual Scientific Meeting (China) on September, 2011 in Xi An, China.
5. Qing Wang. Platform presentation at the 3rd World Congress of Asian Psychiatry on August, 2011 in Melbourne, Australia.
6. Qing Wang. Platform presentation at the 10th National Neurochemistry Meeting (China) on July, 2011 in Zhengzhou, China.
7. Qing Wang. Platform presentation at the the 9th Biennial Meeting of the Asia Pacific Society for Neurochemistry on October, 2010 in Bangkok, Thailand.
8. Qing Wang. Platform presentation at the the 7th National PD Annual Meeting (China) on May, 2010 in Shanghai, China.
9. Qing Wang. Platform presentation at the 9th National Neurochemistry Meeting (China) on July, 2009 in Changsha, China.
10. Qing Wang .Platform presentation at the Tiantan International Stroke Meeting on June, 2009 in Beijing, China.
11. Qing Wang. Travel award obtained in the 8th Biennial Meeting of the Asia Pacific Society for Neurochemistry from June 27th to July 1st , 2008 in Beijing, China.
12. Qing Wang, Xiannan Tang, Swanson RA, Midori A. Yenari. Platform Presentation at the 59th American Academy of Neurology Annual Meeting on May 2nd, 2007 in Boston, MA, USA;
13. Qing Wang, Xiannan Tang, Midori A. Yenari. Honourable Mention in the Poster Presentation at the American Heart Association’s Young Investigators Forum on September 29th, 2006, in San Francisco, USA.
14. Qing Wang, Xiannan Tang, Aaron HM, Lee KH, Swanson RA, Midori A. Yenari. Lay Language summary in Press Book Part 2, Neuroscience Conference on Oct, 2006, in Atlanta, USA.
15. Qing Wang, Wong PT. Travel award obtained in the 6th Biennial Meeting of the Asia Pacific Society for Neurochemistry from 4th to 7th Feb, 2004 in Hong Kong.
16. Qing Wang, Penghua Wang, Wong PT. Young Scientist Award at 7th NUS-NUH Annual Scientific Meeting on September, 2003 in Singapore.
17. Qing Wang, Penghua Wang, Hongyuan Yang, Wong PT. Platform presentation at the Third International Congress on Vascular Dementia on October 23-26, 2003 in Prague, Czech Republic.
18. Qing Wang, Won NUS Research Scholarship (2001-2005).
19. Qing Wang. Obtained FIRST CLASS REWARD at National Medical Competition of Solicit Article (China) on December, 2000.
20. Qing Wang. Won Outstanding Undergraduate Student Scholarship in 1991 and 1992.
